Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial

Barham K. Abu Dayyeh, Daniel B. Maselli, Babusai Rapaka, Thomas Lavin, Mark Noar, Hisham Hussan, Christopher G. Chapman, Violeta Popov, Pichamol Jirapinyo, Andres Acosta, Eric J. Vargas, Andrew C. Storm, Fateh Bazerbachi, Marvin Ryou, Matthew French, Sabrena Noria, Daniel Molina, Christopher C. Thompson

Research output: Contribution to journalArticlepeer-review


Background: Intragastric balloons are anatomy-preserving, minimally invasive obesity therapies. Enhanced tolerance and durability could help broaden clinical adoption. We investigated the safety and efficacy of an adjustable intragastric balloon (aIGB) in adults with obesity. Methods: In this prospective, multicentre, open-label, randomised clinical trial done at seven US sites, adults aged 22–65 years with obesity were randomly assigned (2:1) to aIGB with lifestyle intervention or lifestyle intervention alone (control) for 32 weeks. Balloon volume could be increased to facilitate weight loss or decreased for tolerability. Coprimary endpoints included mean percentage total bodyweight loss and responder rate (≥5% total bodyweight loss) at 32 weeks. We used a multiple imputed intention-to-treat population analysis. This study was registered with, NCT02812160. Findings: Between Aug 9, 2016, and Dec 7, 2018, we randomly assigned 288 patients to aIGB (n=187 [65%]) or control (n=101 [35%]) groups. Mean total bodyweight loss at 32 weeks was 15·0% (95% CI 13·9–16·1) in the aIGB group versus 3·3% (2·0–4·6) in the control group (p<0·0001). Clinical response was observed in 171 (92%) patients in the aIGB group. Adjustments to the aIGB occurred in 145 (80%) patients for weight loss plateau or intolerance. Upward volume adjustment facilitated an additional mean 5·2% (4·5–5·8) total bodyweight loss. Downward volume adjustment allowed 21 (75%) patients in the aIGB group to complete the full duration of therapy. Intolerance caused early removal of the device in 31 (17%) patients. No micronutrient deficiencies were observed in the aIGB cohort. Device-related serious adverse events were observed in seven (4%) patients, without any deaths. Interpretation: When aIGB was combined with lifestyle modification, significant weight loss was achieved and maintained for 6 months following removal. Balloon volume adjustability permitted individualised therapy, maximising weight loss and tolerance. Funding: Spatz Medical.

Original languageEnglish (US)
Pages (from-to)1965-1973
Number of pages9
JournalThe Lancet
Issue number10315
StatePublished - Nov 27 2021

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial'. Together they form a unique fingerprint.

Cite this